Navigation Links
Nektar Therapeutics' President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
Date:1/3/2008

SAN CARLOS, Calif., Jan. 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and CEO Howard W. Robin will deliver the corporate presentation at the upcoming JPMorgan 26th Annual Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California on Tuesday, January 8, 2008, at 4:30 p.m. Pacific Time.

The presentation will be accessible through a live audio and slideshow webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until January 22, 2008.

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar PEGylation and pulmonary technology, expertise, and manufacturing capabilities have enabled ten approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

Nektar Therapeutics

201 Industrial Road

San Carlos, CA 94070

650-631-3100 Phone 650-631-3150 Fax


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2016)... , ... May 18, 2016 , ... Ryan Benton was ... life expectancy in the late teens to early twenties. DMD is a relatively common ... at the age of 22, Benton’s condition was critical. He met with the founder ...
(Date:5/17/2016)... , ... May 17, 2016 , ... ... and BioSmartSA, a healthcare consultancy based in Saudi Arabia, have formed a partnership ... to healthcare providers in the Kingdom of Saudi Arabia (KSA). , The ...
(Date:5/17/2016)... 17, 2016 Strekin AG, ... Basel, Switzerland announced today the ... P38 mitogen-activated protein kinase.      (Logo: ... will build the necessary research foundation for the ... MAP Kinases play fundamental roles. Pamapimod has a ...
(Date:5/17/2016)... ... 17, 2016 , ... HOLLOWAY AMERICA, a stainless steel pressure vessel and tank ... on Thursday, May 19 in St. Louis, Missouri. The event will be held at ... a vendor showcase during the early afternoon of the event, where the company’s representatives ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):